SCHEDULE: Vanguard Group Discloses 4.87% Stake in Sutro Biopharma

The Vanguard Group reported a 4.87% beneficial ownership stake in Sutro Biopharma Inc., holding 4,115,250 shares of common stock as of June 30, 2025.

Summary

• The Vanguard Group, an investment adviser based in Malvern, PA, filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Sutro Biopharma Inc.
• As of June 30, 2025, The Vanguard Group beneficially owned an aggregate of 4,115,250 shares of Sutro Biopharma Inc. Common Stock.
• This ownership represents 4.87% of the class of securities.
• The Vanguard Group holds sole dispositive power over 4,083,877 shares and shared dispositive power over 31,373 shares.
• The Vanguard Group holds no sole or shared voting power over these shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This filing is a routine disclosure of beneficial ownership and does not contain information that would typically influence sentiment beyond the fact of a large institutional holding.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor's stake provides transparency regarding the ownership structure of Sutro Biopharma Inc.

Key Dates

Keywords

Sutro Biopharma, Vanguard Group, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biopharma